Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | ABL1 | P00519 | 12/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18398581 | 0.87 | JAK2 (0.53) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18409108 | 0.85 | JAK1 (0.47) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18409202 | 0.84 | TYK2 (0.53) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18409365 | 0.83 | GSK3B (0.44) | TYK2JAK2JAK1JAK3GSK3B | |
| SCHEMBL18409345 | 0.82 | JAK2 (0.50) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18409103 | 0.81 | JAK2 (0.43) | TYK2JAK2JAK1JAK3GSK3B | |
| SCHEMBL18409287 | 0.81 | JAK2 (0.47) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18409176 | 0.80 | TYK2 (0.48) | TYK2JAK2JAK1JAK3ABL1 | |
| SCHEMBL18398295 | 0.79 | MAP2K2 (0.40) | ABL1MAPK14 | |
| SCHEMBL18398296 | 0.78 | JAK2 (0.37) | TYK2JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017012647-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS | GALAPAGOS NV (BE) | 2017-01-26 | — | — | WO | disclosed |